Silo Pharma, Inc.(SILO)

Biotechnology · Sarasota, FL

$1.44-0.05 (-3.36%)

Delayed quote: Oct 6, 2026, 3:04 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:08:13.125Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:08:13.125Z.

Quote observation: 2026-10-06T19:04:54.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,625,198
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 3,277,095
TTM operating EBITDA · period ending 2026-06-30: -4,449,849

FMP input reference: 5fded3d3484fa1cf7e618a907758d95a7a48bcc7542cb4bc7c8f037a45079178

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SILO EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

SILO Competitors' EV/EBITDA Ratio

SILO

Silo Pharma, Inc.

Current

Market Cap

$1.63M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LABT

Lakewood-Amedex Biotherapeutics, Inc.

vs SILO

Market Cap

$1.51M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELAB

PMGC Holdings Inc.

vs SILO

Market Cap

$1.46M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TCRT

Alaunos Therapeutics, Inc.

vs SILO

Market Cap

$1.79M

EV/EBITDA Ratio

N/A

TTM Avg

570.22x

3Y Avg

570.22x

5Y Avg

570.22x

CRIS

Curis, Inc.

vs SILO

Market Cap

$1.48M

EV/EBITDA Ratio

N/A

TTM Avg

341.73x

3Y Avg

341.73x

5Y Avg

341.73x

NXGL

NEXGEL, Inc.

vs SILO

Market Cap

$1.44M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IVF

INVO Fertility, Inc.

vs SILO

Market Cap

$1.43M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RNAZ

TransCode Therapeutics, Inc.

vs SILO

Market Cap

$1.82M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TNON

Tenon Medical, Inc.

vs SILO

Market Cap

$1.85M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

JUNS

Jupiter Neurosciences, Inc.

vs SILO

Market Cap

$1.40M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Silo Pharma, Inc. (SILO)	$1.63M	N/A	N/A	N/A	N/A
Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs ›	$1.51M	N/A	N/A	N/A	N/A
PMGC Holdings Inc. (ELAB)vs ›	$1.46M	N/A	N/A	N/A	N/A
Alaunos Therapeutics, Inc. (TCRT)vs ›	$1.79M	N/A	570.22x	570.22x	570.22x
Curis, Inc. (CRIS)vs ›	$1.48M	N/A	341.73x	341.73x	341.73x
NEXGEL, Inc. (NXGL)vs ›	$1.44M	N/A	N/A	N/A	N/A
INVO Fertility, Inc. (IVF)vs ›	$1.43M	N/A	N/A	N/A	N/A
TransCode Therapeutics, Inc. (RNAZ)vs ›	$1.82M	N/A	N/A	N/A	N/A
Tenon Medical, Inc. (TNON)vs ›	$1.85M	N/A	N/A	N/A	N/A
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.40M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics

About Silo Pharma, Inc.

Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.

Sarasota, FL

3 employees

silopharma.com

Healthcare / Biotechnology